scispace - formally typeset
L

Laurent Molinier

Researcher at French Institute of Health and Medical Research

Publications -  52
Citations -  1139

Laurent Molinier is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 35 publications receiving 816 citations.

Papers
More filters
Journal ArticleDOI

Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.

Sandrine Andrieu, +132 more
- 01 May 2017 - 
TL;DR: The multidomain intervention and polyunsaturated fatty acids, either alone or in combination, had no significant effects on cognitive decline over 3 years in elderly people with memory complaints.
Journal ArticleDOI

Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials

Nicola Coley, +158 more
TL;DR: Multidomain interventions, targeting multiple risk factors simultaneously, could be effective dementia prevention strategies, but may be burdensome and not universally acceptable.
Journal ArticleDOI

Methodological considerations in cost of prostate cancer studies: a systematic review.

TL;DR: The review showed thatCOI studies adopted significantly different approaches to estimate the costs of prostate cancer, reflecting a lack of consensus on the methodology of COI studies in this area.
Journal ArticleDOI

Economics of the clinical management of lung cancer in France: an analysis using a Markov model.

TL;DR: This model provides a robust economic analysis of the cost of lung cancer management, and will be useful for assessing the economic consequences of future changes in patient management.
Journal ArticleDOI

Exploring the relationship between Alzheimer's disease severity and longitudinal costs.

TL;DR: It was found that the endogeneity of these variables led to a large underestimation of their impact of AD severity on costs, and potential endogeneity should be controlled for to prevent biased estimations of the impact ofAD severity measures on costs.